Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase ...

In the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin (Hb) levels of ...

Novartis has shared positive results from a phase 3b study of Fabhalta (iptacopan) in a new population of patients with the ...

Novartis has unveiled further data for Fabhalta (iptacopan), reinforcing its position in the paroxysmal nocturnal ...

Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.

Novartis Fabhalta shows statistically significant and clinically meaningful improvements in haemoglobin in new population of patients with PNH: Basel Friday, June 13, 2025, 09:00 ...

Patients treated with Fabhalta reported an average improvement in fatigue from baseline of 4.88 points at Day 84 and 4.29 points at Day 168 of the study (as measured by FACIT-Fatigue score) 1 "Today, ...

Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

In the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin (Hb ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...